NTSR1 and prostate carcinoma: Moreover, the selective NTR1 antagonist SR48692 is able to inhibit the neurotensin-induced growth of prostate cancer cells [6], suggesting the involvement of NTR1 as an oncogenic receptor in prostate cancer.